By Li Yu and Peng Chao
The Singapore-Sichuan High-Tech Innovation Park, a joint venture of Singapore and Sichuan province, received the second round of investment in early July.
Five companies, most focused on medicine and information technology, signed cooperation agreements worth 3.7 billion yuan ($ 590 million) in total with the park.
In February, the park signed cooperation agreements with another five partners, involving a total investment of 6.7 billion yuan.
The five companies in the second round are the Singapore-based Hong Leong Group, Beijing TRS Information Technology Ltd, Good Doctor Pharmaceutical Group, Nanjing Sample Technology Group and Chengdu Aipu Internet Ltd.
Hong Leong Group, an innovative key property player in Singapore, will establish a foreign-funded enterprise in the park, and invest 1 billion yuan to build a commercial complex with top-level hotel service, apartments and shopping malls.
Nanjing Sample Technology Group, one of China’s best private innovative hi-tech industrial groups, whose leading businesses are intelligent traffic, modern logistics and health services, will invest 700 million yuan to build an Internet of Things (IOT) Center.
Chengdu Aipu Internet Ltd, a local company in Chengdu, plans to build a cluster composed of a management center, cloud technology and other Internet technologies R&D center, and a training center.
Good Doctor Pharmaceutical Group, a leading domestic medical company, will set its headquarters and drug R&D center in the park. Beijing TRS Information Technology Ltd plans to build a big data R&D base.
The Singapore-Sichuan High-Tech Innovation Park (SSCIP) in Chengdu is the first high-tech industrial park jointly developed by Singapore and the Sichuan government. It will focus on eight pillar industries - IT, biomedicine, service outsourcing, new digital media, precision engineering, environmental technology, finance and training.
Source: China Daily
